Aethlon Medical Inc.
AEMD evidence brief
What we can confirm
- BioSniper Score:
- 4.8 / 10
- Market Cap:
- $4.5M
- Cash Runway:
- 7.8 mo
What it means
What to watch
Prepared research question
What matters most for AEMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AEMD
Aethlon Medical Inc. (AEMD) is a clinical-stage medical therapeutic company developing the Hemopurifier, an investigational blood filtration device for oncology and viral infections, with no revenue and a cash runway of at least twelve months as of mid-2026.
Key risk: Zero revenue and no near-term sales
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Aethlon Medical Inc..
Aethlon Medical Inc. (AEMD) is a clinical-stage medical therapeutic company developing the Hemopurifier, an investigational blood filtration device for oncology and viral infections, with no revenue and a cash runway of at least twelve months as of mid-2026.
- Aethlon Medical is a clinical-stage medical therapeutic company focused on developing the Hemopurifier, an immunotherapeutic device for cancer, life-threatening viral infections, and organ transplantation [sec · filed 2026-07-01].
- Cash and equivalents were $4.9M as of 2026-06-30, with net income of -$1.5M and shareholders' equity of $5.2M [sec].
- The company reported no revenue for fiscal years ended March 31, 2026 and March 31, 2025 [sec · filed 2026-07-01].
- The independent Data Safety Monitoring Board (DSMB) approved advancement to the third cohort of the oncology trial after completion of the second cohort in March 2026 [sec · filed 2026-07-01].
- Three clinical sites in Australia are open for enrollment in a safety, feasibility and dose-finding oncology trial targeting 9-18 patients [sec · filed 2026-07-01].
What works
- The Hemopurifier has been safely used in 173 sessions with 44 patients in human studies, demonstrating potential to remove life-threatening viruses [sec · filed 2026-07-01].
- The DSMB recommended progression to the final third cohort of the oncology trial, indicating acceptable safety and feasibility [news · published 2026-03-24].
- Management believes cash and equivalents as of June 30, 2026, plus post-quarter stock sale proceeds, will fund planned operations for at least twelve months [sec_mda · as of 2026-08-13].
What to weigh
- The company generated no revenue in fiscal years 2025 and 2026 and may never achieve profitability [sec · filed 2026-07-01].
- Additional capital will be required to continue advancing the Hemopurifier beyond the current twelve-month runway [sec_mda · as of 2026-08-13].
- The company canceled a planned clinical trial in India to conserve resources, citing extended timelines for site activation and execution [sec · filed 2026-07-01].
- Some patents may expire before FDA or foreign approval is obtained, though newer patents may provide protection [sec · filed 2026-07-01].
From the filings
Quoted directly from source documents.
No revenue generated in recent fiscal years
“We did not generate any revenue during the fiscal years ended March 31, 2026 and March 31, 2025.”
SEC filings · July 1, 2026
DSMB approved advancement to third cohort
“In March 2026, the Company completed the second cohort and the DSMB subsequently approved advancement to the third cohort of the study.”
SEC filings · July 1, 2026
Cash runway of at least twelve months
“we believe that our cash and cash equivalents as of June 30, 2026, together with the proceeds received from sales of common stock subsequent to quarter end, will be sufficient to fund our planned operations for at least twelve months”
SEC MD&A · August 13, 2026
Hemopurifier safely used in 173 sessions with 44 patients
“In human studies, 173 sessions with 44 patients, the Hemopurifier was safely utilized and demonstrated the potential to remove life-threatening viruses.”
SEC filings · July 1, 2026
Risks & what to watch (4)›
Key risks
- Zero revenue and no near-term sales — No revenue in FY2025 or FY2026; profitability depends on successful commercialization, which is uncertain [sec · filed 2026-07-01].
- Cash runway limited to ~12 months — Management expects cash to last at least 12 months but will need additional capital beyond that period [sec_mda · as of 2026-08-13].
- Patent expiration risk — Some patents may expire before FDA or foreign approval; newer patents may not fully protect the technology [sec · filed 2026-07-01].
- Clinical trial execution uncertainty — Indian trial canceled due to extended timelines; patient recruitment may occur more rapidly than expected, increasing costs [sec · filed 2026-06-22].
What to watch
- Progress of the third cohort in the Australian oncology trial, including enrollment and safety data [sec · filed 2026-07-01].
- Any new financing or strategic collaborations to extend cash runway beyond the current twelve-month estimate [sec_mda · as of 2026-08-13].
- Regulatory milestones with the FDA, including qualification of an additional key component supplier [sec · filed 2026-07-01].
- Potential revenue from government contracts or grants, which have not been secured for the current period [sec · filed 2026-07-01].
Sources: News · SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Aethlon Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aethlon Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
7.8 months
D/E 0.20 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Short Interest
as of May 12, 2026- % of float
- 0.9%
- Days to cover
- 1.1
- Shares short
- 14,050
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AEMD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aethlon Medical Inc.?
Aethlon Medical Inc. (AEMD) is a clinical-stage medical therapeutic company developing the Hemopurifier, an investigational blood filtration device for oncology and viral infections, with no revenue and a cash runway of at least twelve months as of mid-2026.
What is Aethlon Medical Inc.'s lead drug candidate?
Aethlon Medical Inc.'s most advanced tracked candidate is hemopurifier (Phase 1) for Solid tumors in patients with stable or progressive disease during anti-PD-1 monotherapy.
Who is the CEO of Aethlon Medical Inc.?
Mr. James B. Frakes M.B.A. is the chief executive officer of Aethlon Medical Inc. (AEMD).
Where is Aethlon Medical Inc. headquartered?
Aethlon Medical Inc. (AEMD) is headquartered in San Diego, CA, United States.
What therapeutic areas does Aethlon Medical Inc. focus on?
Aethlon Medical Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.